In preparation for the 2014 World Orphan Drug Congress in Geneva, we have collated a number of interviews from some of the leading orphan drug developers. The industry-at-large are investing more and more resources into rare disease research, and numerous companies are now deploying the scientific, regulatory and strategic expertise to progressed an orphan drug to market.
With over 7000 known rare diseases, the opportunities both in a healthcare and commercial context are tremendous. This eBook holds key insight and top tips about how to overcome development challenges, how to establish fruitful strategic partnerships, what needs to be displayed to payers to demonstrate value and what the foreseeable game changers and opportunities may be that will affect the future of the industry. The feedback was assembled following several interviews conducted with confirmed speakers for the World Orphan Drug Congress Europe 2012.
The speaker faculty for the 4th Annual World Orphan Drug Congress is being finalised this month and so far there has been unprecedented interest and endorsement from the global biopharma and rare disease industry. Take a look at the sponsoring organisations here and book today to get involved with the leading figures of the orphan drug industry, expand your rare disease network and share ideas to create new solutions to meet your business objectives in this space.
For more updates on Pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D